Navigation Links
Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
Date:4/20/2011

BUFFALO, N.Y., April 20, 2011 /PRNewswire/ --  Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

KX01 (KX2-391) is a potent, orally available small molecule Src kinase/pretubulin dual mechanism inhibitor discovered and currently developed by Kinex Pharmaceuticals using its proprietary technology platforms Mimetica™ and Opal™. KX01 differentiates itself as an inhibitor that targets the kinase substrate pocket and therefore, offers an excellent efficacy as well as safety profile. The composition of matter of KX01 is covered by issued patents.

KX01 has been shown to be very effective against a broad range of cancers in both in vitro experiments and in animal cancer models. Importantly, the compound has synergistic/additive activities with most first line chemotherapeutic agents. A completed Phase I study, in patients with end-stage cancer, showed a desirable safety profile and clinical response in approximately 25% of the patients. Clinical data support either once or twice daily dosing. Phase II studies are ongoing.  

Under the terms of the agreement, Hanmi Pharmaceuticals will acquire the rights to the development and commercialization of KX01 for all oncology indications in certain Asian territories, including Korea, greater China and some Southeast Asian Countries. Japan, India, Australia and New Zealand are not included in this agreement. 

Hanmi Pharmaceuticals will assume all development responsibility and associated costs in the licensed territories and will participate with Kinex Pharmaceuticals on Phase III global registration studies. Hanmi Pharmaceuticals will also provide Kinex Pharmaceuticals with an up-front payment, milestone payments and royalties. A joint development team will be establis
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
2. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
4. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
5. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
6. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
7. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
8. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 Cardinal Health today announced ... Group (THDG). A distributor of generic pharmaceuticals, over-the-counter medications and ... THDG was owned by Court Square Capital Partners. The ... cash and new debt.  Headquartered in ... Group had revenues of approximately $450 million in 2014. ...
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/58tdl6/pharmaceutical ) has ... Chloride Market by Applications, by Region - Industry Trends ... The pharmaceutical grade sodium chloride market is ... and 2019 in terms of volume, and the consumption ... The report on Pharmaceutical grade sodium chloride market, ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
Breaking Medicine Technology:Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
(Date:7/6/2015)... ... 06, 2015 , ... With a new community program in ... with Family Emergency Shelter Coalition (FESCO) and announced a new charity campaign to ... to provide emergency services and support for homeless families, all the while moving ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... In a ... learn how to reduce their risk of having a fracture through the bone health ... Fractures Awareness Day. , “We are participating because our residents need this information to ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School of Public Health ... a three-year effort to reduce rates of diabetes and cardiovascular disease in African-American ... the Morehouse School of Medicine’s Prevention Research Center and the Satcher Health Leadership ...
(Date:7/6/2015)... MD (PRWEB) , ... July 06, 2015 , ... Dr. ... and Washington, DC, area patients. Kybella is a non-surgical method to dissolve ... use of reducing moderate to severe fat deposits under the chin, commonly known as ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® REmind® Screws. ... Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 posterior lumbar ...
Breaking Medicine News(10 mins):Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3
... following is being,issued by the U.S. Conference of Catholic ... Visit to the United States, WHO: Deirdre McQuade ... bishops of the United States. She is available for ... and New York,City., During his first U.S. visit, ...
... those who took 2,000 IUs a day lived 26% longer ... consume very high levels of vitamin E seem to live ... The study comes on the heels of growing concerns regarding ... suffering from Alzheimer,s or another illness -- the high dosage ...
... As the State of Nebraska,s Chief,Medical Officer, ... large-scale,public health issues. The same goes for Gary ... University Medical Center. Right now, both,physicians are focusing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/LATU118LOGO ), Dr. Schaefer, ...
... 24, NAPA, Calif., April 15 Senetek PLC ... the development,of technologies that target the science of healthy ... December 31, 2007., Revenue for the year ended ... 2006. Revenues for the fourth quarter of 2007,were $223,000, ...
... minutes during their,workday, DALLAS, April 15 April ... The call to action is,simple: Americans should fit 30 ... that American jobs have become more sedentary and that,employees ... did 20 years ago. The,Start! movement works with employers ...
... to the European Advertising and Medical Education ... ... healthcare marketing,executive with more than 15 years strategic and business-building,experience, has joined ... Development, Europe. GHG Grey,Healthcare Group (GHG) is a WPP company and one ...
Cached Medicine News:Health News:High Doses of Vitamin E Lengthen Lives of Alzheimer's Patients 2Health News:High Doses of Vitamin E Lengthen Lives of Alzheimer's Patients 3Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 2Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 3Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 4Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 2Health News:Start! Walking America: The American Heart Association's National Start! Walking Day Is April 16 3Health News:Susan Byrne joins GHG Grey Healthcare Group as EVP, Strategy and Business Development, Europe, a Newly-Created Position 2
... ring electrodes feature a molded grip ... slider that moves smoothly and locks ... also feature ultraflexible, red-and-black, 61-cm (24-in) ... resistance of bend-relief protection at both ...
... bars made of silver/silver chloride have contacts ... easy separation into two individual tabs. For ... 17). Bar dimensions: 4 cm (1.6 in) ... 200-count package contains 50 individually sealed sets ...
... Video Camera System (NTSC)With Maxenon PowerPlus ... surgeon's eye view of any procedure. ... or digital files for later use. ... 8" to 36". Automatic Iris and ...
... and your patient warm, with the ... system.,Designed around the Coanda Effect, thousands ... air flow around your torso's blush ... the heat and stress induced environment ...
Medicine Products: